Cancer cells can be destroyed more effectively and selectively with a unique new reusable treatment

Led by Professor Peter J. Sadler from Warwick's Department of Chemistry, researchers have developed a new line of attack against cancer: an organic-osmium compound, which is triggered using a non-toxic dose of sodium formate, a natural product found in many organisms, including nettles and ants.

Named JPC11, it targets a metabolic process which cancer cells rely on to survive and multiply. It does this by converting a key substance used by cancer cells to provide the energy they need for rapid division (pyruvate) into an unnatural lactate - leading to the cells' destruction.

Uniquely, this chemo-catalyst treatment can be recycled and reused within a cancer cell to attack it repeatedly.

This unprecedented functional ability to recycle and reuse the compound within cancer cells could lead to future anticancer drugs being administered in smaller, more effective, and potentially less toxic doses - decreasing the side-effects of chemotherapy.

The researchers have been focusing on the potential to use this compound on ovarian and prostate cancers.

Ovarian cancers are becoming increasingly resistant to existing chemotherapy drugs (such as the platinum drug, cisplatin). Since this new research functions in a totally new and unique way, it may overcome this acquired resistance and widen the spectrum of anticancer activity.

Importantly, the development opens up a possibility for a more selective cancer treatment as JPC11 was observed to specifically target the biochemistry of cancer cells, leaving healthy cells largely untouched - another improvement compared to existing platinum-based drugs, which can also attack non-cancerous cells.

Dr James Coverdale, a Research Fellow from Warwick's Department of Chemistry, commented: "This is a significant step in the fight against cancer. Manipulating and applying well-established chemistry in a biological context provides a highly selective strategy for killing cancer cells.

"We have discovered that chemo-catalyst JPC11 has a unique mechanism of action – and we hope that this will lead to more effective, selective and safer treatments in the future."

Professor Peter Sadler, a medicinal chemist at the University of Warwick commented: "Platinum compounds are the most widely used drugs for cancer chemotherapy, but we urgently need to respond to the challenges of circumventing resistance and side-effects. Our lab is focussed on the discovery of truly novel anticancer drugs which can kill cells in totally new ways. Chemo-catalysts, especially those with immunogenic properties, might provide a breakthrough.

"It will take time to progress from the lab to the clinic, but we are fortunate to have a talented enthusiastic, international team working with colleagues in Warwick Cancer Research Centre across the borderlines of chemistry, cell and systems biology and cancer medicine who are determined to succeed."

Professor Martin Wills, catalyst specialist at the University of Warwick, commented: "Although asymmetric catalytic hydrogenation processes are well developed in the materials industry, this research provides the first ever example of it being achieved inside cells using a synthetic catalyst."

Handedness (molecular asymmetry) is critical to the function of bio-molecules in the body. Proteins, enzymes and our DNA, for example - are handed. Only the correct hand works, in the same way that a right hand does not fit a left-hand glove.

In this case, the osmium compound JPC11, with sodium formate, can selectively produce a molecule of a specific 'handedness' - thus manipulating how cancer cells grow.

James P C Coverdale, Isolda Romero-Canelón, Carlos Sanchez-Cano, Guy J Clarkson, Abraha Habtemariam, Martin Wills, Peter J Sadler.
Asymmetric transfer hydrogenation by synthetic catalysts in cancer cells.
Nature Chemistry. doi: 10.1038/nchem.2918

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...